PDEI-5 for erectile dysfunction: a potential role in seizure susceptibility.

ABSTRACT

INTRODUCTION: There is a high prevalence of erectile dysfunction (ED) in men with epilepsy; however, few studies have been conducted concerning the treatment of ED in this neurological group. AIM: The main purpose of this review is to highlight the influence of phosphodiesterase type 5 inhibitor (PDEI-5) for ED on seizure susceptibility. METHODS: All available online articles with information pertaining to PDEI-5 and seizure susceptibility were included in this review. MAIN OUTCOME MEASURES: The main outcome assessed demonstrated the intriguing role of PDEI-5 and its metabolites on seizure susceptibility. RESULTS: Case reports in men without epilepsy described seizure occurrence and electrophysiological changes following sildenafil, tadalafil, or vardenafil treatment. Consistent with these findings, preclinical studies suggested a proconvulsant effect of PDEI-5 on models of seizure induction. CONCLUSIONS: Evidence suggests an influence of PDEI-5 on seizure susceptibility in humans. In addition, preclinical studies have demonstrated the role of nitric oxide metabolites in the facilitation of paroxysmal phenomenon. Although there are many causes of seizures, medical professionals should be aware of the possible influence of PDEI-5 on seizure susceptibility. Further investigation by physicians and scientists is required to improve our understanding of this important topic.